Mar. 28 at 2:38 PM
$WHWK 10-K filed
https://www.sec.gov/ix?doc=/Archives/edgar/data/1422142/000162828025015269/aadi-20241231.htm
• 46,784,618 outstanding shares as of Mar 24
• Plan to submit HWK-007 IND in treating solid tumors, including NSCLC and PROC, in 2H 2025
• Plan to submit HWK-016 IND for the treatment of ovarian cancer by end of 2025.
• Plan to complete HWK-206 IND-enabling studies and linker-payload process development in 2025 and first half of 2026, with IND submission mid-2026.
•
$47.2 million on Dec 31. Added
$202.4 million in March from FYARRO divestiture & PIPE financing. Expect to pay
$38 million April 2025 to Wuxi Biologics for the in-licensing of the ADC Therapies. Cash runway into 2028.